Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
SKRR to Commence Uranium Drill Program to Test Conductors at Clearwater West (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

VentriPoint Diagnostics Ltd V.VPT

Alternate Symbol(s):  VPTDF

Healthcare Medical Devices
Ventripoint Diagnostics Ltd is a Canada-based medical device company. The Company is engaged in the development and commercialization of diagnostic tools that monitor patients with heart disease. It is developing a suite of applications for all heart diseases and imaging modalities, including congenital heart disease, pregnancy, pulmonary hypertension, COVID-19, imaging, and cardiotoxicity in oncology patients. The Company’s Ventripoint Medical System (VMS+) is a diagnostic aid that was developed to provide a point-of-care solution to better communicate the heart’s structure and function without the need for magnetic resonance imaging (MRI). VMS+ enhances ultrasound, providing three-dimensional (3D) technology that allows for visualization of all four chambers of the heart. The system’s proprietary Knowledge Based Reconstruction (KBR) technology creates 3D models of the heart and calculates volumes and ejection fractions equivalent to the gold-standard Magnetic resonance imaging (MRI).


TSXV:VPT - Post by User

VentriPoint Diagnostics Ltd
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(91)
•••
Post by jopatcloon May 21, 2024 12:27pm
79 Views
Post# 36050161

Exciting events and breakthroughs are on the horizon! 🚀

Exciting events and breakthroughs are on the horizon! 🚀
An Unforgettable Evening at the Angiopro Partner Dinner during EuroPCR2024

Last night, EuroPCR2024 participants had the extraordinary opportunity to connect with our esteemed partner, Angiopro. The event was alive with dynamic discussions, groundbreaking insights, and the fortification of our collaborative bonds.

A profound thank you to the incredible Angiopro team for their unwavering support and dedication in representing and introducing the Ventripoint VMS+ to the European audience. Your engagement propels us forward, fueling innovation in the cardiologic field.

Stay tuned and keep Ventripoint on your radar as we continue to push boundaries and achieve remarkable milestones together. Exciting events and breakthroughs are on the horizon!

Benjamin Joas Rieck Christian Ugarenko Jan Mller-Nielsen

EuroPCR2024 Angiopro Ventripoint CardiologyNetworking HealthcareInnovation

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities